Compare Five Below Inc (FIVE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Novo Nordisk A/S — how do they compare? Five Below Inc trades at $213.87 (market cap $11.55B), while Novo Nordisk A/S trades at $38.48 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 14.3× Five Below Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Novo Nordisk A/S for 116 Days on average.
| FIVE | NVO | |
|---|---|---|
Market Cap | $11.55B | $165.31B |
Volume | 1,120,554 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $63.98 |
52-Week Low | $138.49 | $35.29 |
Typical Hold Time | 46 Days | 116 Days |
Enterprise Value | $12.40B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $213.30, up 4.44% today, with strong earnings beats in recent quarters and a bullish analyst consensus of 60% buy ratings. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600 million buyback and board appointments.
Outlook remains positive with revenue projected to grow to $5.3 billion in 2026 and net income margin improving to 11.65%. Risks include premium valuation (P/E 18.81) and execution pressure amid economic headwinds. The consensus price target of $298.44 suggests 40% upside potential from current levels.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
